Polymorphisms in catechol-o-methyltransferase modify treatment effects of aspirin on risk of cardiovascular disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 9, 2014, Pages 2160-2167

  Hall, Kathryn T ^a,c   Nelson, Christopher P ^d   Davis, Roger B ^a,c   Buring, Julie E ^b,c   Kirsch, Irving ^a,c,e   Mittleman, Murray A ^c,f   Loscalzo, Joseph ^b,c   Samani, Nilesh J ^d   Ridker, Paul M ^b,c   Kaptchuk, Ted J ^a   Chasman, Daniel I ^b,c  

^a Program in Placebo Studies Division of General Medicine and Primary Care Department of Medicine   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e UNIVERSITY OF PLYMOUTH   (United Kingdom)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

aspirin; catecholamines; vitamin E

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; CATECHOL METHYLTRANSFERASE; METHIONINE; PLACEBO; VALINE;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMT GENE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ASPIRIN; CATECHOLAMINES; VITAMIN E;

AMINO ACID SUBSTITUTION; ASPIRIN; CARDIOVASCULAR DISEASES; CATECHOL O-METHYLTRANSFERASE; FEMALE; FOLLOW-UP STUDIES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INCIDENCE; META-ANALYSIS AS TOPIC; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; VITAMIN E;

EID: 84906934633     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.303845     Document Type: Article

References (37)

1. Voutilainen S, Tuomainen TP, Korhonen M, Mursu J, Virtanen JK, Happonen P, Alfthan G, Erlund I, North KE, Mosher MJ, Kauhanen J, Tiihonen J, Kaplan GA, Salonen JT. Functional COMT Val158Met polymorphism, risk of acute coronary events and serum homocysteine: the Kuopio ischaemic heart disease risk factor study. PLoS One. 2007;2:e181.
2. Wittstein IS. Stress cardiomyopathy: a syndrome of catecholamine-mediated myocardial stunning? Cell Mol Neurobiol. 2012;32:847-857.
3. Zhu BT. On the mechanism of homocysteine pathophysiology and pathogenesis: a unifying hypothesis. Histol Histopathol. 2002;17:1283-1291.
4. Kanasaki K, Palmsten K, Sugimoto H, Ahmad S, Hamano Y, Xie L, Parry S, Augustin HG, Gattone VH, Folkman J, Strauss JF, Kalluri R. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature. 2008;453:1117-1121.
5. Miyaki K, Htun NC, Song Y, Ikeda S, Muramatsu M, Shimbo T. The combined impact of 12 common variants on hypertension in Japanese men, considering GWAS results. J Hum Hypertens. 2012;26:430-436.
6. Htun NC, Miyaki K, Song Y, Ikeda S, Shimbo T, Muramatsu M. Association of the catechol-O-methyl transferase gene Val158Met polymorphism with blood pressure and prevalence of hypertension: interaction with dietary energy intake. Am J Hypertens. 2011;24:1022-1026.
7. Annerbrink K, Westberg L, Nilsson S, Rosmond R, Holm G, Eriksson E. Catechol O-methyltransferase val158-met polymorphism is associated with abdominal obesity and blood pressure in men. Metabolism. 2008;57:708-711.
8. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6:243-250.
9. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, Herman MM, Apud J, Egan MF, Kleinman JE, Weinberger DR. Functional analysis of genetic variation in catechol-Omethyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet. 2004;75:807-821.
10. Ghimire LV, Kohli U, Li C, Sofowora GG, Muszkat M, Friedman EA, Solus JF, Wood AJ, Stein CM, Kurnik D. Catecholamine pathway gene variation is associated with norepinephrine and epinephrine concentrations at rest and after exercise. Pharmacogenet Genomics. 2012;22:254-260.
11. Haase-Fielitz A, Haase M, Bellomo R, Lambert G, Matalanis G, Story D, Doolan L, Buxton B, Gutteridge G, Luft FC, Schunck WH, Dragun D. Decreased catecholamine degradation associates with shock and kidney injury after cardiac surgery. J Am Soc Nephrol. 2009;20:1393-1403.
12. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, Maixner W, Diatchenko L. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science. 2006;314:1930-1933.
13. Bialecka M, Kurzawski M, Klodowska-Duda G, Opala G, Tan EK, Drozdzik M. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications. Pharmacogenet Genomics. 2008;18:815-821.
14. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860
15. Fuster V, Sweeny JM. Aspirin: a historical and contemporary therapeutic overview. Circulation. 2011;123:768-778.
16. Final report on the aspirin component of the ongoing physicians' health study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med. 1989;321:129-135
17. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
18. von Känel R, Dimsdale JE. Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo. Eur J Haematol. 2000;65:357-369.
19. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294:56-65.
20. Ridker PM, Chasman DI, Zee RY, Parker A, Rose L, Cook NR, Buring JE; Women's Genome Health Study Working Group. Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy American women. Clin Chem. 2008;54:249-255.
21. Schunkert H, König IR, Kathiresan S, et al; Cardiogenics; CARDIoGRAM Consortium. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43:333-338.
22. The Coronary Artery Disease (C4D) Genetics Consortium. A genomewide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet. 2011;43:339-344.
23. Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE. Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med. 2000;9:19-27.
24. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010; 466:707-713.
25. Ehret GB, Munroe PB, Rice KM, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103-109.
26. Deloukas P, Kanoni S, Willenborg C, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45:25-33.
27. Stramentinoli G, Gualano M, Algeri S, de Gaetano G, Rossi EC. Catecholo- methyl transferase (COMT) in human and rat platelets. Thromb Haemost. 1978;39:238-239.
28. Spatz M, Kaneda N, Sumi C, Nagatsu I, Creveling CR, Nagatsu T. The presence of catechol-o-methyltransferase activity in separately cultured cerebromicrovascular endothelial and smooth muscle cells. Brain Res. 1986;381:363-367.
29. Gellekink H, Muntjewerff JW, Vermeulen SH, Hermus AR, Blom HJ, den Heijer M. Catechol-O-methyltransferase genotype is associated with plasma total homocysteine levels and may increase venous thrombosis risk. Thromb Haemost. 2007;98:1226-1231.
30. Hill LD, York TP, Kusanovic JP, Gomez R, Eaves LJ, Romero R, Strauss JF III. Epistasis between COMT and MTHFR in maternal-fetal dyads increases risk for preeclampsia. PLoS One. 2011;6:e16681.
31. Karolczak K, Kamysz W, Karafova A, Drzewoski J, Watala C. Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study. Pharmacol Res. 2013;74:7-22.
32. Herrera-Galeano JE, Becker DM, Wilson AF, Yanek LR, Bray P, Vaidya D, Faraday N, Becker LC. A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability. Arterioscler Thromb Vasc Biol. 2008;28:1484-1490.
33. Kim SH, Jeong HH, Cho BY, Kim M, Lee HY, Lee J, Wee K, Park HS. Association of four-locus gene interaction with aspirin-intolerant asthma in Korean asthmatics. J Clin Immunol. 2008;28:336-342.
34. Chasman DI, Shiffman D, Zee RY, Louie JZ, Luke MM, Rowland CM, Catanese JJ, Buring JE, Devlin JJ, Ridker PM. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2009;203:371-376.
35. Wright B, Gibson T, Spencer J, Lovegrove JA, Gibbins JM. Plateletmediated metabolism of the common dietary flavonoid, quercetin. PLoS One. 2010;5:e9673.
36. Higashi O, Ishigaki W. Effects of vitamin E on the platelet aggregation induced by combined adenosine diphosphate and hydrogen peroxide. Tohoku J Exp Med. 1977;121:41-46.
37. Preuss M, König IR, Thompson JR, et al; CARDIoGRAM Consortium. Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet. 2010;3:475-483.